Literature DB >> 24530524

RBM10 regulates alternative splicing.

Akira Inoue1, Naoki Yamamoto2, Masatsugu Kimura3, Koji Nishio4, Hideo Yamane5, Koichi Nakajima6.   

Abstract

RBM10, originally called S1-1, is a nuclear RNA-binding protein with domains characteristic of RNA processing proteins. It has been reported that RBM10 constitutes spliceosome complexes and that RBM5, a close homologue of RBM10, regulates alternative splicing of apoptosis-related genes, Fas and cFLIP. In this study, we examined whether RBM10 has a regulatory function in splicing similar to RBM5, and determined that it indeed regulates alternative splicing of Fas and Bcl-x genes. RBM10 promotes exon skipping of Fas pre-mRNA as well as selection of an internal 5'-splice site in Bcl-x pre-mRNA. We propose a consensus RBM10-binding sequence at 5'-splice sites of target exons and a mechanistic model of RBM10 action in the alternative splicing.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alternative splicing; Bcl-x; Fas; RBM10; RBM5; S1-1

Mesh:

Substances:

Year:  2014        PMID: 24530524     DOI: 10.1016/j.febslet.2014.01.052

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  27 in total

1.  The genetics of splicing in neuroblastoma.

Authors:  Justin Chen; Christopher S Hackett; Shile Zhang; Young K Song; Robert J A Bell; Annette M Molinaro; David A Quigley; Allan Balmain; Jun S Song; Joseph F Costello; W Clay Gustafson; Terry Van Dyke; Pui-Yan Kwok; Javed Khan; William A Weiss
Journal:  Cancer Discov       Date:  2015-01-30       Impact factor: 39.397

2.  The nuclear splicing factor RNA binding motif 5 promotes caspase activation in human neuronal cells, and increases after traumatic brain injury in mice.

Authors:  Travis C Jackson; Lina Du; Keri Janesko-Feldman; Vincent A Vagni; Cameron Dezfulian; Samuel M Poloyac; Edwin K Jackson; Robert S B Clark; Patrick M Kochanek
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

3.  A detrimental mutation on USP40 unlocks the tumorigenesis in a rare case of lung cancer.

Authors:  Zhi-Hong Xu; Hui Wang; Xiao-Yang Ji; Fei-Xu Zhang; Bei-Li Gao; Jia-An Hu; Jing Zheng
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

4.  Nuclear Magnetic Resonance Structure of a Novel Globular Domain in RBM10 Containing OCRE, the Octamer Repeat Sequence Motif.

Authors:  Bryan T Martin; Pedro Serrano; Michael Geralt; Kurt Wüthrich
Journal:  Structure       Date:  2015-12-17       Impact factor: 5.006

5.  Binding site discovery from nucleic acid sequences by discriminative learning of hidden Markov models.

Authors:  Jonas Maaskola; Nikolaus Rajewsky
Journal:  Nucleic Acids Res       Date:  2014-11-11       Impact factor: 16.971

6.  Tumor suppressor properties of the splicing regulatory factor RBM10.

Authors:  Jordi Hernández; Elias Bechara; Doerte Schlesinger; Javier Delgado; Luis Serrano; Juan Valcárcel
Journal:  RNA Biol       Date:  2016       Impact factor: 4.652

7.  Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.

Authors:  Shigeki Nanjo; Wei Wu; Niki Karachaliou; Collin M Blakely; Junji Suzuki; Yu-Ting Chou; Siraj M Ali; D Lucas Kerr; Victor R Olivas; Jonathan Shue; Julia Rotow; Manasi K Mayekar; Franziska Haderk; Nilanjana Chatterjee; Anatoly Urisman; Jia Chi Yeo; Anders J Skanderup; Aaron C Tan; Wai Leong Tam; Oscar Arrieta; Kazuyoshi Hosomichi; Akihiro Nishiyama; Seiji Yano; Yuriy Kirichok; Daniel Sw Tan; Rafael Rosell; Ross A Okimoto; Trever G Bivona
Journal:  J Clin Invest       Date:  2022-07-01       Impact factor: 19.456

8.  Prp40 pre-mRNA processing factor 40 homolog B (PRPF40B) associates with SF1 and U2AF65 and modulates alternative pre-mRNA splicing in vivo.

Authors:  Soraya Becerra; Marta Montes; Cristina Hernández-Munain; Carlos Suñé
Journal:  RNA       Date:  2015-01-20       Impact factor: 4.942

9.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.

Authors:  Agnieszka K Witkiewicz; Elizabeth A McMillan; Uthra Balaji; GuemHee Baek; Wan-Chi Lin; John Mansour; Mehri Mollaee; Kay-Uwe Wagner; Prasad Koduru; Adam Yopp; Michael A Choti; Charles J Yeo; Peter McCue; Michael A White; Erik S Knudsen
Journal:  Nat Commun       Date:  2015-04-09       Impact factor: 14.919

Review 10.  Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation.

Authors:  Zhihui Dou; Dapeng Zhao; Xiaohua Chen; Caipeng Xu; Xiaodong Jin; Xuetian Zhang; Yupei Wang; Xiaodong Xie; Qiang Li; Cuixia Di; Hong Zhang
Journal:  J Exp Clin Cancer Res       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.